Cargando…
Dupilumab-Induced Pancreatitis
Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies. By using scoring...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365188/ https://www.ncbi.nlm.nih.gov/pubmed/37492485 http://dx.doi.org/10.14309/crj.0000000000001106 |
_version_ | 1785076993638793216 |
---|---|
author | Jasti, Vivek V. McCarthy, Sean T. Govani, Shail M. |
author_facet | Jasti, Vivek V. McCarthy, Sean T. Govani, Shail M. |
author_sort | Jasti, Vivek V. |
collection | PubMed |
description | Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies. By using scoring systems to identify DIP, we have identified another case of suspected DIP. In this study, we present a case of pancreatitis 10 days after initiation of dupilumab. An evaluation for other causes was unrevealing. As dupilumab use increases, providers should be aware of this possible adverse effect. |
format | Online Article Text |
id | pubmed-10365188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-103651882023-07-25 Dupilumab-Induced Pancreatitis Jasti, Vivek V. McCarthy, Sean T. Govani, Shail M. ACG Case Rep J Case Report Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies. By using scoring systems to identify DIP, we have identified another case of suspected DIP. In this study, we present a case of pancreatitis 10 days after initiation of dupilumab. An evaluation for other causes was unrevealing. As dupilumab use increases, providers should be aware of this possible adverse effect. Wolters Kluwer 2023-07-21 /pmc/articles/PMC10365188/ /pubmed/37492485 http://dx.doi.org/10.14309/crj.0000000000001106 Text en © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Report Jasti, Vivek V. McCarthy, Sean T. Govani, Shail M. Dupilumab-Induced Pancreatitis |
title | Dupilumab-Induced Pancreatitis |
title_full | Dupilumab-Induced Pancreatitis |
title_fullStr | Dupilumab-Induced Pancreatitis |
title_full_unstemmed | Dupilumab-Induced Pancreatitis |
title_short | Dupilumab-Induced Pancreatitis |
title_sort | dupilumab-induced pancreatitis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365188/ https://www.ncbi.nlm.nih.gov/pubmed/37492485 http://dx.doi.org/10.14309/crj.0000000000001106 |
work_keys_str_mv | AT jastivivekv dupilumabinducedpancreatitis AT mccarthyseant dupilumabinducedpancreatitis AT govanishailm dupilumabinducedpancreatitis |